CTOs on the Move

K-LaB Technologies

www.klabtech.com

 
K-LaB Technologies, Inc. is a Dripping Springs, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.klabtech.com
  • 600 Winchester Dr
    Dripping Springs, TX USA 78620
  • Phone: 310.432.6400

Executives

Name Title Contact Details

Similar Companies

Accera div Nestle Corp

Accera div Nestle Corp is a Broomfield, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Atmofizer

The world’s most innovative and effective clean air technology against harmful ultra fine particles incl. COVID-19. Developed in Germany, assembled in the US.

Armune

Armune BioScience, Inc. develops and commercializes molecular diagnostic and prognostic tests for prostate, lung, and breast cancers that will allow physicians and patients to make more personalized treatment decisions. The company was founded by members of the Apjohn Group, LLC, a business accelerator that brings together valuable resources of management talent and angel/seed financing. The company’s corporate headquarters are in Kalamazoo, MI and the laboratory is in Ann Arbor, MI.

Velicept Therapeutics

Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs.

Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.